Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors
25 September 2023 - 2:00PM
Business Wire
- Dr. Gheuens is the Chief Medical Officer and
Head of R&D of Agios Pharmaceuticals, Inc. -
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical
company focused on discovering and developing potential
best-in-class medicines for serious and rare diseases, today
announced the appointment of Sarah Gheuens, M.D., Ph.D., to its
Board of Directors. Dr. Gheuens is the Chief Medical Officer (CMO)
and Head of R&D of Agios Pharmaceuticals, Inc.
“Sarah’s extensive global clinical development and regulatory
experience, including oversight of Phase 3 programs through
regulatory submissions and launch, will prove extraordinarily
valuable as Viridian advances its late-stage candidates for the
potential benefit of patients living with thyroid eye disease
(TED),” said Tomas Kiselak, Chairperson of the Viridian
Therapeutics Board of Directors. “We’re fortunate to be able to
strengthen the Board with a physician-scientist of Sarah’s caliber,
and I very much look forward to working with her.”
Dr. Gheuens joined Agios in 2019, was promoted to CMO in 2021,
and assumed leadership of the R&D organization in 2022. During
her time at Agios, she has overseen early- and late-stage clinical
development globally across multiple indications, including
pyruvate kinase deficiency, thalassemia, and sickle cell
disease.
“I’m thrilled to be joining the Board of an organization so
clearly committed to addressing areas of high unmet medical need
among patients affected by serious and rare diseases, particularly
those in the complex autoimmune space,” said Dr. Gheuens. “I’ve
dedicated much of my career to developing medicines for underserved
patient populations across a range of therapeutic areas. I’m
excited to leverage my experience to support the Viridian team as
it focuses on delivering potentially first- and best-in-class
therapies to change the treatment paradigm for TED.”
Prior to Agios, Dr. Gheuens held roles of increasing
responsibility at Biogen in the areas of safety, medical affairs,
and clinical development. Before transitioning to industry, she was
a clinician at Boston’s Beth Israel Deaconess Medical Center
(BIDMC), taking care of patients with HIV and neurological
complications while also researching progressive multifocal
leukoencephalopathy. Dr. Gheuens received her medical degree from
the Free University of Brussels (VUB), Belgium, and completed her
neurology residency at the University Hospital of the Free
University of Brussels, Belgium, followed by an HIV/neurology
fellowship at BIDMC. She also holds a Ph.D. in Medical Sciences
from the University of Antwerp, Belgium, and a Master’s in Medical
Sciences from Harvard Medical School.
About Viridian Therapeutics
Viridian Therapeutics is a biopharmaceutical company focused on
engineering and developing potential best-in-class medicines for
patients with serious and rare diseases. Viridian’s expertise in
antibody discovery and engineering enables it to develop
differentiated therapeutic candidates for previously validated drug
targets in commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the
treatment of patients with thyroid eye disease (TED). The Company
is conducting its first global Phase 3 trial called THRIVE to
evaluate the safety and efficacy of VRDN-001 in patients with
active TED. Viridian is also planning a second Phase 3 trial,
called THRIVE-2, to evaluate the safety and efficacy of VRDN-001 in
patients with chronic TED. In addition to its intravenously
administered VRDN-001 program, the Company is advancing three
candidates for its subcutaneous strategy with the goal of providing
a more conveniently administered therapy to patients with TED.
Viridian is developing multiple preclinical assets in autoimmune
and rare diseases.
Viridian is based in Waltham, Massachusetts. For more
information, please visit https://www.viridiantherapeutics.com.
Follow Viridian on LinkedIn and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230925962260/en/
Investors: Louisa Stone, 508-808-2400 Manager, Investor
Relations IR@viridiantherapeutics.com
Media: Matt Fearer, 617-272-4605 Vice President, Corporate
Communications Media@viridiantherapeutics.com
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024